Market Trends of Infertility Drugs Industry
Gonadotrophins Segment is Expected to Witness Growth Over the Forecast Period
Gonadotrophins are hormones that the anterior pituitary produces and releases. They act on the gonads (testes and ovaries) to boost the production of sex hormones and encourage either ova or sperm production. Gonadotrophins are a component of fertility treatments that help women induce ovulation and develop mature follicles. In men, it boosts sperm counts during fertility treatment.
The gonadotrophin segment is anticipated to witness significant growth in the infertility drugs market over the forecast period owing to factors such as the high efficacy of gonadotrophins to treat infertility issues among the population and new product launches. For instance, according to an article published in Cell in May 2022, male infertility was an increasing and serious medical concern that affected approximately half of infertile couples worldwide.
An article published in the International Bar Association in March 2022 showed that fertility rates consistently declined to below replacement levels across developed countries globally. This is anticipated to fuel the demand for drugs to treat infertility problems, propelling the segment's growth.
Moreover, the rising number of new product launches increases the availability of effective drugs in the market. For instance, in June 2024, Kissei Pharmaceutical Co. Ltd inked a licensing deal with JW Pharmaceutical Corporation. This agreement grants JW Pharmaceutical the rights to develop and commercialize the GnRH antagonist, linzagolix, specifically in the Korean market.
Therefore, owing to the factors above, such as the high prevalence of infertility cases, the rising number of research studies, and new product launches, the segment is anticipated to grow over the forecast period.
North America is Expected to Hold Significant Market Share Over the Forecast Period
North America is anticipated to hold a significant share of the market due to the rising infertility problems, menopausal disorders, urinary infections, thyroid problems, endometriosis, and others due to busy lifestyles and a rise in stress among women. In addition, increasing demand for more advanced infertility drugs and growing company activities are also contributing to market growth.
The number of male fertility cases is rising due to increased levels of smoking, consumption of alcohol, use of certain illicit drugs, and underlying conditions such as obesity. For instance, according to the University of New Orleans, in May 2023, in the United States, about 11% of women and about 9% of men of childbearing age were infertile. The rising prevalence of smoking is associated with a high level of ferroptosis in seminal plasma, which affects the quality of semen and lowers the probability of getting pregnant. This is expected to propel the growth of the market studied over the forecast period.
Furthermore, the increasing government and company initiatives to promote fertility treatment are also contributing to the high demand for fertility drugs in the market. For instance, in June 2024, the American Society for Reproductive Medicine began endorsing the HOPE with Fertility Services Act (HR 8821). This legislation will ensure that the discrimination against those who need medical care to build their families will come to an end. Such initiatives are expected to raise awareness among the population regarding fertility treatment, which is anticipated to fuel market growth.
Therefore, owing to the factors above, the market studied is anticipated to grow over the forecast period.
